Tag Archives | antibody-drug conjugates

Roller Coaster Market Creates Biotech Buying Opportunity…Update-1

Update-1 August 19…  Dawg Days of August Biotech stocks remain weak with momentum plays hit the hardest. The IBB could test the recent bottom of 359 hit on reversal day last Friday and another low on August 7. There is strong support at this level so any multi-day breakdown would  break the upward trend channel. The more […]

Continue Reading 0

2015 Rayno Biopharmaceutical Stock Portfolio

Updated 8/12/15 Company Ticker Original Start Price $ 5 Yr High RaynoTotal Price 8/12 YTD % Perform % Perform Abbvie ABBV 3/25/2014 51.7 70.76 33 68.76 5 Alexion ALXN* 2/2/2009 17.5 203.3 994 191 3.2 Alkermes ALKS 3/22/2013 23 75.17 191 67.88 15.9 Albany Molec AMRI 2/10/2011 4.32 23.95 391 21.23 30.4 Amgen AMGN 2/2/2009 […]

Continue Reading 0

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0

Biotech Stocks Hit New Highs-Large Caps Lead The Way…Update-2 June 25

Update -2 … June 25… IBB off all time high of 379.97 SCOTUS opinion in favor of ACA (ObamaCare) is favorable to hospital stocks and positive for HC sector overall as we have assumed since 2010. The XLV Health Care Select SPDR ETF is up 11.25% YTD and 162.5% over five years. The bull market […]

Continue Reading 0

ASCO 2015 Biotech Movers Day Two: FCSC, JUNO, RXDX

Update-1 BLUE Drops 1.96% and 1.77% After Hours 6/3 In the bubbly CAR-T world bluebird bio (BLUE) and Celgene announced a deal for   for development of product candidates for B-cell maturation antigen (BMCA) utilizing bluebird bios’s gene therapy technology to modify a patient’s own T-Cells to target cancer cells. A $25M up-front payment was made but […]

Continue Reading 0